Trial Profile
A retrospective, single-center, case-control trial of alemtuzumab based conditioning regimen instead of anti-thymocyte globulin in patient undergoing allogeneic stem cell transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Antithymocyte globulin
- Indications Transplant rejection
- Focus Therapeutic Use
- 16 Oct 2016 New trial record